Trial Profile
Open, Non-randomized, Sequential Group Comparison to Investigate the Pharmacokinetics, Safety, and Tolerability of 100 mg SPM 927 in Male and Female Subjects With Renal Impairment Including Subjects Requiring Dialysis Compared With Male and Female Healthy Subjects Following Single-dose Administration.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 May 2015
Price :
$35
*
At a glance
- Drugs Lacosamide (Primary)
- Indications Generalised seizures; Pain; Partial epilepsies
- Focus Pharmacokinetics
- Sponsors UCB
- 05 May 2015 New trial record